Schiffon Wong

As healthcare delivery systems undergo unprecedented transformation, there is now an increasing realization that medical care is a negotiated process.

Perspective

My conviction that that research evidence should inform complex, population level, health-related decisions has been the continuous thread of my career. As healthcare delivery systems undergo unprecedented transformation, there is now an increasing realization that medical care is a negotiated process. As such, patient-centered care has become a focal component of healthcare improvement. I am energized by the opportunity to innovate in the scientific application of patient experience data to decision-making processes across stakeholders and the product lifecycle.  As we aim to improve health outcomes by integrate innovative therapeutics into the context of patient’s lives our systematic consultation, involvement, and partnership with patients will enhance the value of medical products across all stakeholders. 

I am energized by the opportunity to innovate in the scientific application of patient experience data to decision-making processes across stakeholders and the product lifecycle.

Schiffon Wong

Executive Director, Global Evidence & Value Development

Profile

Joined Merck KGaA, Darmstadt, Germany: 2013

Key research fields and topics:

  • Public Health
  • Patient-Focused Drug Development
  • Health Economics and Outcomes Research
  • Health Technology Assessment
  • Real-World Evidence
  • Health Services Research
  • Interpersonal Dimensions of Care
  • Behavioral Psychology
  • Medical Decision Making

Prizes and awards:

  • Winner of the 2018 Merck KGaA, Darmstadt, Germany Performance Award: Driving financial performance, business aspirations and priorities while exceeding customer expectations as a core team member for MAVENCLAD European Union Approval and Launch Readiness. 
  • Clinical & Research Excellence Awards Best in Health Economics and Outcomes Research finalist, 2018
  • Scrips Awards finalist for Best Use of Real-World Evidence, 2018

View My Linkedin Profile

CV & Scientific activities

CV: Education

CV: Education

BA in Behavioral Psychology & Psychopharmacology at the CUNY Baccalaureate Program
MPH in Epidemiology at Columbia University
Doctoral level training in Health Services Research

References

Invited Speaker Engagements

  • Lappin, D.R., Wong, S.L., & Kennedy, A. (2018, November). “Potential Caregiver Roles in Medical Product Development.” National Summit: The Family Caregiver’s Role in Patient-Focused Medical Product Development. Washington, D.C.
  • Clarke, C.P., Williams, R., & Wong, S.L., (2015, June). “How Industry Pursues Internal and External Cross-Functional Collaborations During Drug Development to Optimize Market Access After Regulatory Approval.” Emerging Practices in Product Commercialization Planning: How Cross Collaboration Is Redefining Product Development Planning Symposium Session at the DIA 51st Annual Meeting. Washington, D.C.

Peer-Reviewed Manuscripts

  • Le, H.V., Truong, C.T.L., Kamauu, A., Holmen, J, Fillmore, C., Graham, C., Crooke, H., Kobayashi, M., Martin, C., Sabidó-Espin, M., & Wong, S.L., (2018). Identifying Patients with Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Health Care Data. Value in Health. Advance online publication.
  • Hettle, R., Harty, G., & Wong, S.L., (2018). Cost-effectiveness of cladribine tablets, alemtuzumab and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Journal of Medical Economics. 21(7):676-686. 
  • Siddiqui, M., Khurana, I., Budhia, S., Hettle, R., Harty, G., & Wong, S.L., (2017). Systematic Literature Review and Network Meta-Analysis of Cladribine Tablets versus alternative Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Current Medical Research and Opinion. 34(8):1361-1371. 
  • Ernst, F.R., Barr, P., Elmor R., & Wong, S.L., (2017). Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Current Medical Research and Opinion. 33(12):2099-2106. 
  • Choti, M.A., Thomas, M., Wong, S.L., Eaddy, M., Pawlik, T.M., Hirose, K., Weiss, M.J., Kish, J., & Green, M.R., (2016). Surgical Resection Preferences and Perceptions Among Medical Oncologists Treating Liver Metastases From Colorectal Cancer. Annals of Surgical Oncology. 23(2):375-81. 
  • Dobbels, F., Wong, S.L., You, M., & Kalsekar, A., (2014). Beneficial Effect of Belatacept on Health-Related Quality of Life and Perceived Side-Effects: Results from the BENEFIT and BENEFIT-EXT Trials. Transplantation. 98(9):960-8.  

Manuscripts In Review

  1. Le, H.V., Truong, C.T.L., Kamauu, A., Holmen, J, Fillmore, C., Graham, C., Crooke, H., Kobayashi, M., Martin, C., Sabidó-Espin, M., & Wong, S.L., (2018). Identifying Relapses in Relapsing-Remitting Multiple Sclerosis Patients Using EHR- and Claims-based Algorithms Applied to United States Integrated Delivery Network Healthcare Data. 
  2. Jonker, M., Donkers, B., Goossens, L., Hoefman, R., Jabbarian, L., De Bekker-Grob, E., Versteegh, M., Harty, G., & Wong, S.L., (2018). Summarizing Patients’ Preferences for the Entire Competitive Landscape of Multiple Sclerosis Treatment Options.
  3. Bell Gorrod, H., Latimer, N.R., Damian, D., Hettle, R., Harty, G.T. & Wong, S.L., (2018). Adjusting for Treatment Switching in the Relapse-Remitting Multiple Sclerosis CLARITY Trial and CLARITY Extension 
  4. Bell Gorrod, H., Latimer, N.R., Damian, D., Hettle, R., Harty, G.T. & Wong, S.L., (2018). Impact of Non-Randomised Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
  5. Spelman, T., Freilich, J., Anell, B., Wong, S.L., & Hillert, J. (2018). Evidence of Unmet Need in High Disease Activity Relapsing-Remitting Multiple Sclerosis – A Population-Based Study in Sweden.

Peer-Reviewed Workshops

  1. McBurney, R.N., Brichetto, G., Balzani, F., & Wong, S.L., Patient-Focused Drug Development and Patient-Centered Clinical Care: Working Together. International Society for Pharmacoeconomics and Outcomes Research 21st Annual European Congress. November 2018.
  2. Le, H.V., Kamauu, A.W.C., Kobayashi, M.G., & Wong, S.L., Improving Performance of Algorithms to Power Unmet Need and Effectiveness in Health Economics and Outcomes Research Using Electronic Health Records and Healthcare Claims Data Sources. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. November 2017.

Peer-Reviewed Oral Podium Presentations

  1. Kamauu, A.W.C., Holmen, J.R., Fillmore, C.L., Le, H.V., Wilson, A., Truong, C.T.L., Martin, C., & Wong, S.L., Performance of Electronic Health Record- and Healthcare Claims-Based Algorithms to Identify Relapsing-Remitting Multiple Sclerosis in U.S. Integrated Delivery Network Healthcare Database. American Medical Informatics Association 2017 Annual Symposium.
  2. Le, H.V., Kobayashi, M.G., Kamauu, A.W.C., Holmen, J.R., Fillmore, C.L., Truong, C.T.L., & Wong, S.L., Identifying Relapsing-Remitting Multiple Sclerosis in United States Integrated Delivery Network Healthcare Electronic Health Record Data. 33rd  International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 2017.  
  3. Le, H.V., Truong, C.T.L., Kamauu, A., Holmen, J., Fillmore, C.L., Sabidó-Espin, M., & Wong, S.L., Lessons Learned in Identifying Relapsing-Remitting Multiple Sclerosis in United States Integrated Delivery Network Healthcare Claims and Electronic Health Record Data. International Society for Pharmacoeconomics and Outcomes Research. May 2017.
  4. Irish, W., Wong, S.L., Bowers, D., Trivedi, D., & Hebden, T., Association between Early Changes in Chronic Kidney Disease Stage Following Kidney Transplantation and Graft Survival. Rapid oral at the 15th Congress of the European Society for Organ Transplantation. September 2011.
  5. Weinstein, R., Rahman, M.I., Wilcox, M., Matcho, A., & Wong, S.L., Assessing the Major Drivers for the Increased Healthcare Costs Associated with Colorectal Cancer. International Society for Pharmacoeconomics and Outcomes Research. May 2009.
Peer-Reviewed Poster Presentations
 
  1. Treharne, C., Harty, G., Budhia, S., & Wong, S.L., A Cost-Minimization Analysis of Cladribine Tablets versus Alternative High Efficacy Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom. International Society for Pharmacoeconomics and Outcomes Research 21st Annual European Congress. November 2018.
  2. Treharne, C., Harty, G., Budhia, S., & Wong, S.L., A Budget Impact Analysis of Cladribine Tablets versus Alternative High Efficacy Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom. International Society for Pharmacoeconomics and Outcomes Research 21st Annual European Congress. November 2018.
  3. Harty, G.T., Damian, D., Budhia, S., Hettle, R., & Wong, S.L., Subsequent Disease Modifying Drug Treatment of Patients Treated with Cladribine Tablets. Association of British Neurologists Annual Meeting. May 2018.
  4. Wong, S.L., Aldridge, J., Hettle, R., Khurana, I.S., & Siddiqui, M.K., Analysis of 6-Month Confirmed Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a. Americas Committee for Treatment and Research in Multiple Sclerosis Forum. February 2018.
  5. Truong, C.T.L., Kamauu, A.W.C., Graham, C., Crooke, H.R., Holmen, J.R., Fillmore, C.L., Sabidó-Espin, M., & Wong, S.L., Identifying Relapses in Relapsing-Remitting Multiple Sclerosis Patients Using United States Integrated Delivery Network Claims-Based Algorithms. Americas Committee for Treatment and Research in Multiple Sclerosis Forum. February 2018.
  6. Le, H.V., Truong, C.T.L., Kamauu, A.W.C., Martin, C., Holmen, J.R., Fillmore, C.L., Sabidó-Espin, M., & Wong, S.L., Using Claims-Based Algorithms to Identify High Disease Activity for Relapsing-Remitting Multiple Sclerosis Patients in US Healthcare Data. Americas Committee for Treatment and Research in Multiple Sclerosis Forum. February 2018.
  7. Bell Gorrod, H., Latimer, N.R., Damian, D., Hettle, R., Harty, G.T. & Wong, S.L., Adjusting for Treatment Switching in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and CLARITY EXTENSION. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. November 2017.
  8. Bell Gorrod, H., Latimer, N.R., Damian, D., Hettle, R., Harty, G.T. & Wong, S.L., Impact Of Non-Randomised Drop-Out On Treatment Switching Adjustment In The Relapsing-Remitting Multiple Sclerosis CLARITY Trial And The CLARITY EXTENSION Study. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. November 2017.
  9. Wong, S.L., von Hohnhorst, P., Hettle, R., & Konings, P., Health State Utilities in Patients with Relapsing Remitting Multiple Sclerosis treated with Cladribine Tablets. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. November 2017.
  10. Spelman, T., Geale, K., Anell, B., Hillert, J., & Wong, S.L., The Association Between Disease Activity And Health-Related Quality Of Life In RRMS Patients. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. November 2017.
  11. Spelman, T., Geale, K., Anell, B., Hillert, J., & Wong, S.L., Clinical Characteristics and Treatment Patterns of Relapsing-Remitting Multiple Sclerosis Patients with High Disease Activity. MSPARIS2017 7th  JOINT ECTRIMS-ACTRIMS Meeting.
  12. Spelman, T., Geale, K., Anell, B., Hillert, J., & Wong, S.L., The Association between Disease Activity and Disability Progression in Patients with Relapse Remitting Multiple Sclerosis. MSPARIS2017 7th  JOINT ECTRIMS-ACTRIMS Meeting.
  13. Kamauu, A.W.C., Le, H.V., Truong, C.T.L., Crooke, H.R., Holmen, J.R., Fillmore, C.L., Sabidó-Espin, M., & Wong, S.L., Using Algorithms to Identify High Disease Activity Relapsing-Remitting Multiple Sclerosis Patients Using Electronic Health Record Data with Natural Language Processing. MSPARIS2017 7th  JOINT ECTRIMS-ACTRIMS Meeting.
  14. Kamauu, A.W.C., Le, H.V., Truong, C.T.L., Crooke, H.R., Holmen, J.R., Fillmore, C.L., Sabidó-Espin, M., & Wong, S.L., Using United States Integrated Delivery Network Electronic Health Records and Natural Language Processing-Based Algorithms to Identify Relapses in Relapsing-Remitting Multiple Sclerosis Patients. MSPARIS2017 7th  JOINT ECTRIMS-ACTRIMS Meeting.
  15. Kamauu, A.W.C., Le, H.V., Truong, C.T.L., Crooke, H.R., Holmen, J.R., Fillmore, C.L., Sabidó-Espin, M., & Wong, S.L., Developing United States Integrated Delivery Network Claims-Based Algorithms to Identify Relapses in Relapsing-Remitting Multiple Sclerosis Patients. MSPARIS2017 7th  JOINT ECTRIMS-ACTRIMS Meeting.
  16. Truong, C.T.L., Le, H.V., Kamauu, A.W.C., Holmen, J.R., Fillmore, C.L., Kobayashi, M.G., Sabidó-Espin, M., & Wong, S.L., Creating a Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression. ePoster at MSPARIS2017 7th  JOINT ECTRIMS-ACTRIMS Meeting.
  17. Le, H.V., Truong, C.T.L., Kamauu, A.W.C., Holmen, J.R., Fillmore, C.L., Kobayashi, M.G., & Wong, S.L., Identifying Relapsing-Remitting Multiple Sclerosis in United States Integrated Delivery Network Healthcare Claims Data. Poster Spotlight at 33rd  International Conference on Pharmacoepidemiology & Therapeutic Risk Management. August 2017.
  18. Wong, S.L., Elmor, R., Barr, P., & Ernst, F.R., Persistence, Adverse Events, and Relapse in Patients with Relapsing Remitting Multiple Sclerosis and Initiated on IFN Beta-1a or Dimethyl Fumarate. ACTRIMS Forum. February 2017.
  19. Khan, M.M., Wong, S.L., Assessing Adherence to Primary Care Visits after an Emergency Department Episode among Privately-Insured Pediatric Asthma Patients. Agency for Healthcare Research and Quality 22nd Annual National Research Service Award Trainees Conference. June 2016.
  20. Wong, S.L., Fujii, R., & Beckerman, R., Cost Offsets Associated with Rebif Use in 1st Line RRMS: An Analysis Based on the Cochrane Collaboration Review and Real-World Persistence Data. International Society for Pharmacoeconomics and Outcomes Research 18th  Annual European Congress. November 2015.
  21. Wong, S.L., Rutkowski, T., Martin de Bustamante, M.A., Chowdhury, C.A., & Beckerman, R., Modeling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress. November 2014.
  22. Silverio, N., Sequeira, L., & Wong, S.L., Cost-Effectiveness of Subcutaneous versus Intramuscular Interferon Beta-1a in Portugal Based on the Findings of the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress. November 2014.
  23. Silverio, N., Sequeira, L., & Wong, S.L., Financial and Clinical Implications Intramuscular versus Subcutaneous Interferon Beta-1a in Portugal Based on the Findings of the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress. November 2014.
  24. Margolin, K., Wong, S.L., Penrod, J.P., Song, J., Chang, I., Douglas, D.B., Jang, S., Clark, J., & McDermott, D., Effectiveness and Safety of First-Line Ipilimumab for Advanced Melanoma - A U.S. Multisite Retrospective Study. 10th International Meeting of the Society for Melanoma Research. November 2013.
  25. Wong, S.L., Rembert D., Juday, T., Penrod, J.P., Dhanda, R., & Patt, D., Real World Effectiveness of First Line Ipilimumab for Advanced Melanoma in the U.S. Community Setting. 10th International Meeting of the Society for Melanoma Research. November 2013.
  26. Margolin, K., Wong, S.L., Penrod, J.P., Song, J., Chang, I., Douglas, D.B., Jang, S., Clark, J., & McDermott, D., Effectiveness and Safety of First-Line 3mg/kg Ipilimumab Therapy for Advanced Melanoma: Evidence from a U.S. Multisite Retrospective Chart Review. 17th ECCO, 38th ESMO, 32nd ESTRO European Cancer Congress. September 2013.
  27. Patt, D., Wong, S.L., Juday, T., Penrod, J.P., Chen, C., & Hebden, T., A Community-Based, Real-World, Study of Treatment-Naïve Advanced Melanoma Patients Treated with 3mg/kg Ipilimumab in the United States. 17th ECCO, 38th ESMO, 32nd ESTRO European Cancer Congress. September 2013.
  28. Macahilig, C.P., Malinowski, F.J., McGuire, M., Wolthoff, P., Bennett, K., Wong, S.L., & Penrod, J.R., Survival of Patients with Advanced Melanoma in a Real World Setting. International Society for Pharmacoeconomics and Outcomes Research. May 2013.
  29. Malinowski, F.J., McGuire, M., Wolthoff, P., Macahilig, C.P., Bennett, K., Wong, S.L., & Penrod, J.R., Determinants of Initial Treatment for Advanced Melanoma. International Society for Pharmacoeconomics and Outcomes Research. May 2013.
  30. Choti, M.A., Green, M.R., Wong, S.L., Hirose, K., Weiss, M.J., Pawlik, T.M.., Eaddy, M., & Thomas M., Medical Oncologists’ Assessment of Resectability in Patients with Liver-Limited Metastatic Colorectal Cancer. NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™. March 2013.
  31. Choti, M.A., Green, M.R., Corral, M., Wong, S.L., Thomas M., & Eaddy, M., American Medical Oncology Physician Preferences for Combined Modality Therapy Beginning with Systemic Management in Patients with Liver-Limited Metastatic Colorectal Cancer (LL-mCRC). Gastrointestinal Cancers Symposium (ASCO GI). January 2013.
  32. Irish, W., Wong, S.L., Trivedi, D., & Hebden, T., Early Change in Renal Function and Impact on Graft Survival Following Kidney Transplantation: Is There a Differential Effect of Living versus Deceased Donor? American Transplant Congress. June 2012.
  33. Irish, W., Wong, S.L., Trivedi, D., & Hebden, T., Preserving Early Renal Function and Impact on Long-Term Graft Survival Following Kidney Transplantation: Implication for the Number Needed to Treat. American Transplant Congress. June 2012.
  34. Bunnapradist, S., Wong, S.L., Pinsky, B, Liu, F., Taylor, C., Trivedi, D., & Hebden, T., Incidence and Cost of Renal Graft Failure in Commercially Insured Kidney Transplant Recipients. American Society of Nephrology Kidney Week. November 2011.
  35. Bunnapradist, S., Wong, S.L., Pinsky, B, Liu, F., Taylor, C., Trivedi, D., & Hebden, T., Incidence and Costs Associated with New-Onset Diabetes and Cardiovascular Events after Kidney Transplantation in a Commercially Insured Population. American Society of Nephrology Kidney Week. November 2011.
  36. Irish, W., Wong, S.L., Bowers, D., Trivedi, D., & Hebden, T., Chronic Kidney Disease Stage: Impact on Long-Term Graft Survival Following Transplantation. American Society of Nephrology Kidney Week. November 2011.
  37. Irish, W., Wong, S.L., Bowers, D., Trivedi, D., & Hebden, T., Incidence and Costs Associated with New-Onset Diabetes and Cardiovascular Events after Kidney Transplantation in a Medicare Population. American Society of Nephrology Kidney Week. November 2011.
  38. Bunnapradist, S., Wong, S.L., Liu, F., Taylor, C., Trivedi, D., Pinsky, B., & Hebden, T., Renal Function and Cost of Medical Care among Commercially Insured Kidney Transplant Recipients. American Transplant Congress. April 2011. Received an Award of Distinction.
  39. Dobbels, F., Wong, S.L., Joo, S., & Kalsekar, A., Health-Related Quality of Life After Kidney Transplantation: Results from Belatacept Clinical Trials. American Transplant Congress. May 2011.
  40. Dobbels, F., Wong, S.L., You, M., & Kalsekar, A., Patient Reports of Immunosuppressant Related Side-Effects After Kidney Transplantation: Results from the Belatacept Phase III Clinical Trial (BENEFIT). American Transplant Congress. May 2011.
  41. Rahman, M.I., Weinstein, R., Wong, S.L., Matcho, A., Cosmatos, I., & Price, S., An Evaluation of the Economic Burden Associated with Breast Cancer in the First Year After Diagnosis. American Society of Clinical Oncology Breast Cancer Symposium. October 2009.

 

 

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement